These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 21970085)

  • 21. HCV snapshots: macro to micro.
    Huff B
    GMHC Treat Issues; 2003 Oct; 17(10):10-1. PubMed ID: 14689930
    [No Abstract]   [Full Text] [Related]  

  • 22. Focus on hepatitis. Low rate of liver problems seen with LPV/r.
    Carter M
    IAPAC Mon; 2005 Oct; 11(10):325. PubMed ID: 16673499
    [No Abstract]   [Full Text] [Related]  

  • 23. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
    Resino S; Bellón JM; Muñoz-Fernández MA;
    J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377
    [No Abstract]   [Full Text] [Related]  

  • 24. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
    Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
    Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug interactions. Kaletra and ezetimibe.
    TreatmentUpdate; 2006; 18(3):8. PubMed ID: 17209242
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-HIV agents. Monotherapy studies--points to consider.
    TreatmentUpdate; 2008 Jan; 20(1):3-4. PubMed ID: 18320692
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug interactions. Kaletra and atazanavir.
    TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
    [No Abstract]   [Full Text] [Related]  

  • 28. Lopinavir-Ritonavir: a new protease inhibitor.
    Mangum EM; Graham KK
    Pharmacotherapy; 2001 Nov; 21(11):1352-63. PubMed ID: 11714208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Top stories of 2004. Back to the future: lopinavir/ritonavir as "monotherapy".
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):4. PubMed ID: 15717366
    [No Abstract]   [Full Text] [Related]  

  • 30. Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults.
    Yeh RF; Lipman BA; Mayberry C; Miguel B; Nemecek JJ; Gathe JC
    J Int Assoc Physicians AIDS Care (Chic); 2010; 9(5):273-7. PubMed ID: 20841439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA notifications. Generic lopinavir/ritonavir approved by FDA.
    AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatitis coinfection and LPV/RTV.
    Carter M
    IAPAC Mon; 2004 Oct; 10(10):398. PubMed ID: 15801120
    [No Abstract]   [Full Text] [Related]  

  • 33. [An option even for patients with multiple pretreatment].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():97. PubMed ID: 11373796
    [No Abstract]   [Full Text] [Related]  

  • 34. ["Double boosting" passes the test. LPV/r plus SQV in complicated salvage situation].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():85. PubMed ID: 15011607
    [No Abstract]   [Full Text] [Related]  

  • 35. Interaction between lopinavir/ritonavir and warfarin.
    Hughes CA; Freitas A; Miedzinski LJ
    CMAJ; 2007 Aug; 177(4):357-9. PubMed ID: 17698824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New treatment options for HIV-infected patients].
    Wehr A
    Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
    Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kaletra oral solution: modification of confusing label: packaging. an infant died in France.
    Prescrire Int; 2008 Aug; 17(96):140. PubMed ID: 19480095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical data released on ABT-378/r.
    AIDS Read; 2000 Aug; 10(8):468. PubMed ID: 10967805
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.